EL7.AI
Mergers & AcquisitionsMedium•17 September 2026•
2 min read

Aethlon Medical and North Immunology Announce Merger for Antibody Development

Key Facts

1Aethlon Medical announced a definitive merger agreement for an all-stock transaction with North Immunology.
2An oversubscribed $180 million private placement is expected to fund the combined company's operations into H2 2028.
3The merger aims to advance the NOR-101 program for atopic dermatitis, with Phase 1a trials expected to begin in Q1 2027.

In a move reflecting the biotech sector's trend toward consolidation to bolster clinical pipelines, Aethlon Medical has announced a definitive merger agreement with North Immunology in an all-stock transaction. The merger primarily aims to advance the NOR-101 program for atopic dermatitis, with Phase 1a trials expected to commence in early 2027. According to reports, an oversubscribed $180 million private placement has been secured, which is projected to fund the combined company's operations into the second half of 2028.

This transaction significantly strengthens Aethlon Medical's financial position, providing a multi-year cash runway to support clinical research. Under the merger terms, the two companies will combine resources to develop bispecific antibody treatments, leveraging the capital provided by a syndicate of healthcare-focused institutional investors. This step is strategic for securing the long-term funding necessary to navigate the complex and costly clinical development phases inherent in the biopharmaceutical industry.

Regarding stock performance, AEMD closed at $1.43 (close September 16, 2026), reaching a day high of $1.50 per market data. Looking ahead at the economic calendar, there are no direct catalysts for the instrument in the coming seven days; however, investors will be monitoring the formal closing of the merger and the deployment of private placement funds to support the announced clinical trial timeline.